文献速递免疫规划传染病防控与疫情报告

在疫苗安全数据链中使用树状扫描统计识别COVID-19二价加强针接种的安全信号

Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
PubMed 文献 · Vaccine · 2023-07-20

利用树状扫描统计对疫苗安全数据链中≥5岁接种者进行无预先设定结局的广泛监测,分析352,509剂Moderna和979,189剂辉瑞-BioNTech二价疫苗后56天内住院或急诊诊断聚集。Moderna接种后未发现统计学显著聚集;辉瑞-BioNTech接种后检测到未特指不良事件、流感、咳嗽和COVID-19的聚集,呼吸道聚集可能由季节性混杂导致。

要点

  • Moderna二价疫苗接种后未发现统计学显著的诊断聚集。
  • 辉瑞-BioNTech接种后检测到未特指不良事件、流感、咳嗽和COVID-19的聚集。
  • 呼吸道聚集可能因随访期与呼吸道合胞病毒、流感及COVID-19流行重叠所致。

核心结论

  • 仅辉瑞-BioNTech二价疫苗接种后检测到未特指不良事件和随访末期的呼吸道疾病聚集,后者可能由季节性混杂导致。

研究设计与样本

  • 研究采用条件性自我对照树-时间扫描统计,对疫苗安全数据链中≥5岁、截至2022年11月接种Moderna或辉瑞-BioNTech二价COVID-19疫苗者随访56天,分析住院或急诊诊断在ICD-10-CM层级诊断树和时间上的聚集。
  • 分析纳入352,509剂Moderna和979,189剂辉瑞-BioNTech二价疫苗。

主要发现

  • Moderna接种后未发现统计学显著聚集。
  • 辉瑞-BioNTech接种后检测到未特指不良事件聚集(第1-3天,p=0.0001-0.0007)。
  • 辉瑞-BioNTech接种后检测到流感聚集(第35-56天,p=0.0001)、咳嗽聚集(第44-55天,p=0.0002)和COVID-19聚集(第52-56天,p=0.0004)。

关键数值与推荐

  • 统计显著性预设截断值为P=0.01。

局限性

  • 易受时间变化混杂影响。
  • 评估特定结局风险的统计效能低于针对较少结局的传统研究。
  • 可能遗漏在时间上或诊断树内未强聚集的不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditional active vaccine safety monitoring involves pre-specifying health outcomes and biologically plausible outcome-specific time windows of concern, limiting the adverse events that can be evaluated. In this study, we used tree-based scan statistics to look broadly for >60,000 possible adverse events after bivalent COVID-19 vaccination. METHODS: Vaccine Safety Datalink enrollees aged ≥5 years receiving Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine through November 2022 were followed for 56 days post-vaccination. Incident diagnoses in inpatient or emergency department settings were analyzed for clustering within the hierarchical ICD-10-CM diagnosis code "tree" and temporally within post-vaccination follow-up. The conditional self-controlled tree-temporal scan statistic was used, conditioning on total number of cases of each diagnosis and total number of cases of any diagnosis occurring during the scanning risk window across the entire tree. P = 0.01 was the pre-specified cut-off for statistical significance. RESULTS: Analysis included 352,509 doses of Moderna and 979,189 doses of Pfizer-BioNTech bivalent vaccines. After Moderna vaccination, no statistically significant clusters were found. After Pfizer-BioNTech, there were clusters of unspecified adverse events (Days 1-3, p = 0.0001-0.0007), influenza (Days 35-56, p = 0.0001), cough (Days 44-55, p = 0.0002), and COVID-19 (Days 52-56, p = 0.0004). CONCLUSIONS: For Pfizer-BioNTech only, we detected clusters of: (1) unspecified adverse effects, as have been observed in other vaccine studies using this method, and (2) respiratory disease toward the end of follow-up. The respiratory clusters were likely due to overlap of follow-up with the spread of respiratory syncytial virus, influenza, and COVID-19, i.e., confounding by seasonality. The untargeted nature of the method and its inherent adjustment for the many diagnoses and risk intervals evaluated are unique advantages. Limitations include susceptibility to time-varying confounding, lower statistical power for assessing risks of specific outcomes than in traditional studies targeting fewer outcomes, and the possibility of missing adverse events not strongly clustered in time or within the "tree."

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Katherine Yih W, Daley MF, Duffy J, et al. Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink. Vaccine. 2023. PMID: 37479610. doi:10.1016/j.vaccine.2023.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。